NovaBay® Pharmaceuticals, Inc. (NYSE-Amex: NBY) today announced that Roy J. Wu has joined the company as senior vice president for business development. Wu brings to NovaBay® more than 30 years of highly successful experience in the pharmaceutical industry with increasingly responsible management positions in global business development, licensing, international marketing, project management, clinical development, and Pacific sector regulatory and pharmaceutical development.
“The addition of Roy Wu to NovaBay’s executive team is a clear win for the company,” said Ron Najafi, Ph.D., chairman and chief executive officer of NovaBay. “Roy is a seasoned industry veteran and his strong history of developing beneficial partnering and collaborative relationships will be extremely important for NovaBay® as we advance our platform of anti-infective Aganocide® compounds for a broad range of clinical indications worldwide.”
Wu’s areas of expertise include product licensing and technology collaborations, strategic business planning, international marketing, new product planning, and international project management. He has extensive regulatory experience with the U.S. Food and Drug Administration and the Ministry of Health Labor and Welfare (MHLW) in Japan. Among the many strengths Wu adds to NovaBay’s executive team is his deep understanding of Good Clinical Practice (GCP) guidelines and of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), which brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of product registration.
Previously Wu was vice president of business development at Genelabs Technologies Inc., where he was responsible for all business development and licensing activities, including search, evaluation, contract negotiations for all in- and out-license transactions as well as alliance management and assisting in corporate financing activities. At Genelabs, Wu completed numerous licensing agreements and research collaborations with companies including Novartis, Gilead and Affymetrix.
Prior to Genelabs, Wu participated in the 1997 establishment of Kissei Pharma, the U.S. subsidiary of Kissei Pharmaceuticals Co. of Japan. Wu also was director of business development for Quintiles-BRI, a clinical research organization, after working for 16 years at Syntex Corporation. At Syntex, he held numerous positions with increasing responsibility, beginning as a chemist at the Syntex Research Institute of Pharmaceutical Sciences and culminating as director of R&D Program Planning and Management for the company’s Japanese subsidiary.
Wu received his MBA in International Finance from the University of San Francisco, School of Business. He has been a member of the American Association of Pharmaceutical Scientist Planning Committee for Harmonization of Pharmaceutical Science Requirements, the New York Pharma Forum, the Japan Society of Northern California, the Healthcare Study Group (JETRO New York), the Regulatory Affairs Professional Society, and the Licensing Executive Society and Drug Information Association. Wu has been a frequent speaker at conferences including the Bay Bio Panel, Hepatitis C in Search of a Cure, Conducting Clinical Trials in Japan, Pacific Rim Biotech Conference and BIO.
NovaBay® Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide® compounds, which are novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay® has internal development programs aimed at addressing hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide® compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. NovaBay® has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay® and Aganocide® are trademarks of NovaBay® Pharmaceuticals, Inc. For more information on NovaBay, visit: www.novabaypharma.com.
For information, contact:
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson
Mariesa Kemble, 608-850-4745